Holen Sie sich die Stockscreener-App
8.55
5.21%
-0.47
Schlusskurs vom Vortag:
$9.02
Offen:
$8.91
24-Stunden-Volumen:
29,598
Relative Volume:
2.48
Marktkapitalisierung:
$56.26M
Einnahmen:
$43.77M
Nettoeinkommen (Verlust:
$-35.04M
KGV:
-2.6291
EPS:
-3.2521
Netto-Cashflow:
$-5.51M
1W Leistung:
-5.52%
1M Leistung:
-4.79%
6M Leistung:
+2.40%
1J Leistung:
-19.43%
1-Tages-Spanne:
$8.55
$9.00
1-Wochen-Bereich:
$8.55
$9.42
52-Wochen-Spanne:
$6.4652
$12.58
Xilio Therapeutics Inc Stock (XLO) Company Profile
Firmenname
Xilio Therapeutics Inc
Sektor
Branche
Telefon
617-833-1027
Adresse
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
8.55 | 56.26M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | Leerink Partners | Outperform |
| 2022-12-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-16 | Eingeleitet | Guggenheim | Buy |
| 2021-11-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-11-16 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Xilio Therapeutics Inc Aktie (XLO) Neueste Nachrichten
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
A new medical chief gets options to buy 105,000 Xilio shares at $8.91 each. - Stock Titan
Xilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 Plan - Quiver Quantitative
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Two new hires get options on 19,865 Xilio shares - Stock Titan
Xilio (XLO) Results and Estimates: Profit Per Share Surpasses Its Benchmark in Latest Trading; Closing Response: The Stock Gains 0.11% at the ClosePost-Announcement Reaction - vinanet.vn
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Expands By 58.8% - MarketBeat
Weekly Recap: Xilio (XLO) Q2 revenue jump and FDA IND cleared for XTX501 - TradingView
StemPoint group (XLO) discloses 9.5% Xilio Therapeutics stake via warrants - Stock Titan
Xilio Therapeutics earnings beat by $0.25, revenue topped estimates - Investing.com Canada
Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS - MarketBeat
Xilio Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Xilio Therapeutics Q2 Results: Sales up 131% YoY to $18.7M - scanx.trade
Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Xilio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Xilio Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Form 8K Xilio Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Xilio Therapeutics, Inc. 2Q 2026: Revenue $18.7M, EPS $(0.33) — 10-Q Summary - TradingView
Form 8K Xilio Therapeutics Inc For: 12 August By Investing.com - Investing.com India
Xilio Therapeutics reports Q2 2026: $18.7M collaboration revenue, $6.4M net loss, cash $136.0M - TradingView
Xilio Therapeutics (XLO) lifts collaboration revenue and trims net loss in 2026 - Stock Titan
Xilio Therapeutics Reports $18.7 Million Q2 Revenue and FDA Clearance for XTX501 - Quiver Quantitative
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - The Manila Times
Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates - TradingView
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - Yahoo Finance
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - GlobeNewswire
Xilio Therapeutics (XLO) Holds Steady at $9.18 as Biotech Stock Consolidates Near SupportMomentum Factor - dars.gov.et
Xilio Therapeutics (XLO) Holds Steady at $9.18 as Biotech Stock Consolidates Near SupportLong Short Pair - Vinanet
Xilio Therapeutics (XLO) Holds Steady at $9.18 as Biotech Stock Consolidates Near SupportLong Setup Ideas - dars.gov.et
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xilio Therapeutics (XLO) Expected to Announce Earnings on Thursday - MarketBeat
XLO Q2'26 Earnings: revenue estimate is 12.72M USD - TradingView
Xilio Development Inc (NASDAQ: XLO) Share Price, XLO Stock News, XLO Share Price & Updates - kalkine.ca
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEPS Surprise History - vinanet.vn
XLO|Xilio Therapeutics Inc|Price:9.110|Chg%:+0.030 - TradingKey
Xilio Therapeutics Inc (XLO) Cash Flow - TradingKey
Xilio Therapeutics Inc (XLO) Balance Sheet - TradingKey
Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xilio Therapeutics (XLO) Surges 5%: Key Levels to Watch After Breakout MoveLast Point Support - vinanet.vn
Xilio Therapeutics (XLO) Surges 5%: Key Levels to Watch After Breakout MoveDebt Free Companies - www.dars.gov.et
Xilio Therapeutics Inc (XLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xilio Therapeutics Inc (XLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xilio Therapeutics Inc (XLO) Income Statement - TradingKey
XLO|Xilio Therapeutics Inc|Price:9.132|Chg%:+0.482 - TradingKey
Xilio Therapeutics, Inc. Revenue Breakdown – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc. (XLO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Price to earnings forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Finanzdaten der Xilio Therapeutics Inc-Aktie (XLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):